In a study, Cytokinetics’ experimental drug aficamten improved exercise capacity in patients with hypertrophic cardiomyopathy. The data showed patients experienced improvements in peak oxygen uptake. (STAT)
The FDA halted Iovance Biotherapeutics’ lung cancer drug trial after a patient’s death. The company said it plans to work with the FDA to resume enrollment for the lifileucel study. (Yahoo Finance)
Pharma companies focused on obesity, including Novo Nordisk and Eli Lilly, saw significant growth in 2023, even as the rest of the industry underperformed. Analysts predict 15% growth for both Novo and Lilly in 2024. (The Wall Street Journal)
Pharma companies will likely raise drug prices and offer bigger rebates in the wake of the Inflation Reduction Act, according to a letter from the Congressional Budget Office. The CBO said it expects list prices to increase due to the IRA’s inflation-rebate provisions. (Endpoints News)
There has been a shift in abortion litigation since the Supreme Court’s reversal of Roe v. Wade. The current wave of lawsuits focus on when and how emergency medical exceptions apply to abortion bans. (Reuters)
